October 30, 2025

Dompé's Program in NAION Selected for FDA Commissioner’s National Priority Voucher Program

Dompé says it plans to apply the voucher to its Biologics License Application for an intranasal form of nerve growth factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).

Optometric Management

October 30, 2025

Prevent Blindness Offers Patient Education Tools, Resources for Diabetes-Related Eye Disease Month

Prevent Blindness has announced a suite of new educational tools and resources in recognition of Diabetes-related Eye Disease Month this November, aimed at helping patients understand and manage the vision complications associated with diabetes.

Ophthalmology Management

October 06, 2025

Nearly 600 Advocates Unite in Washington for AOA on Capitol Hill 2025

The event provided for a unified, pro-patient message to policymakers

Optometric Management

October 01, 2025

What to Expect When You’re Expecting Ocular Complications From GLP-1 RAs

Despite the effective use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes mellitus, weight management, and cardiovascular risks, research reveals they have known ocular complications.

Optometric Management

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician

April 09, 2025

Port Delivery System With Ranibizumab for Diabetic Eye Disease

Researchers determined that the PDS may decrease the treatment burden of frequent intravitreal injections, but further research on efficacy and safety is needed.

Conexiant

January 16, 2025

LA County Fires Prompt Business Recovery Centers to Open

"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."

Optometric Management

April 02, 2025

GLP-1 RAs Evaluated for Long-Term Risk of NAION in Patients With Diabetes

Researchers’ subgroup analyses provide data on increased risks according to timepoint, demographics, and comorbidities.

Conexiant

August 05, 2025

Large US Study Adds to Connection Between NAION Risks and GLP-1 Drugs

Semaglutide and liraglutide showed the highest risk, while dulaglutide and exenatide were not significantly associated with NAION.

Ophthalmology Management